Triadimefon

Triadimefon is an orally active fungicide. Triadimefon significantly reduces the phosphorylation of AKT1 and ERK1/2. Triadimefon significantly increases pAMPK levels, but does not affect total AMPK levels. Triadimefon inhibits the growth of Saccharomyces cerevisiae, disrupts hormone homeostasis (affecting the synthesis of testosterone, etc.), inhibits fetal adrenal development in rats, induces metabolic shifts in hepatocytes, and impairs spatial learning and memory^{[1][2][3][4][5][6][7]}. In Vitro:Triadimefon (5-50 mg/L) significantly inhibits the growth of Saccharomyces cerevisiae (45%-100% inhibition)^[1].
Triadimefon (0.15-0.3 mM; 3 days) significantly reduces albumin production in primary rat hepatocytes and induces a metabolic shift in hepatocytes (from glycolysis to gluconeogenesis and from fatty acid synthesis to fatty acid oxidation)^[3]. In Vivo:Triadimefon (25-100 mg/kg; p.o.; daily; 10 days (from gestational day 12 to 21)) inhibits fetal adrenal development in rats^[2].
Triadimefon (25-100 mg/kg; p.o.; 9 days (GD 12-GD 20)) significantly reduces serum testosterone level, increases the number of fetal Leydig cells with abnormal aggregation in male fetuses, downregulates testis-related gene and protein expression, induces oxidative stress in pregnant Sprague-Dawley rats^[5].
Triadimefon (20-200 mg/kg; i.p.; once daily; 7 consecutive days) significantly inhibits spatial learning ability, impairs spatial reference memory, and reduces hippocampal retinoic acid (HY-14649) concentration in rats^[7].